import { Placeholder } from "@angular/compiler/src/i18n/i18n_ast";

const tsv_str = `	Name	NameCh	Affiliations	ImgFileName	Description	happyHour	Links


Academic	Chia-Wei Cheng		Assistant Professor, Columbia University	Chia-Wei-Cheng_square.jpeg	<p>I am an assistant professor of Columbia Stem Cell Initiative/Dept. of Genetics and Development. I study stem cell nutrigenomics focusing on the interface of transcriptional and nutritional regulatory networks. Currently, my lab uses intestinal stem cell as an experimental model.</p>	Yes/No	https://www.stemcell.columbia.edu/profile/chia-wei-cheng-phd
Academic	Erica Cai		Assistant Investigator, Indiana Biosciences Research Institute	Erica_Cai_square.jpeg	<p>Erica Cai, PhD, is a biologist who focuses on beta cell protection and diabetes prevention. Her ultimate research goal is to better understand diseases and help to improve patients’ quality of life. In addition to her role at the Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute (IBRI), she also is a member of the Indiana University School of Medicine’s Center for Diabetes and Metabolic Diseases. Prior to joining the IBRI, Cai was an instructor in medicine at the Harvard Medical School. She worked in the laboratory of Dr. Peng Yi and the CRISPR screen core facility at the Joslin Diabetes Center. Her research projects used a multidisciplinary approach to investigate beta cell physiology, including cell regeneration, cell function, stress response and autoimmune protection. Cai was born in Taiwan, studied in Canada and works in the US. She enjoys travel, movies, music, hiking and cooking.</p>	Yes/No	https://www.indianabiosciences.org/cai-lab
Academic	Chih-Chun Lin		Assistant Professor, Columbia University	Chih-Chun_Lin_square.jpeg	<p>Chih-Chun Lin (also goes by Charles) received his medical degree from the National Taiwan University. He subsequently pursued a PhD in Neuroscience at Johns Hopkins, focused on single-cell electrophysiology and neuronal function. Charles then finished his neurology residency at the Houston Methodist Hospital before joining the Movement Disorders Fellowship program at Columbia University, where he was promoted as an assistant professor.</p>	Yes/No	https://www.neurology.columbia.edu/profile/chih-chun-lin-md
Academic	Morgan Sheng		Professor, Broad Institute/MIT	Morgan.jpeg	<p>Morgan Sheng is Core Institute Member, and Co-Director of the Stanley Center for Psychiatric Research, at the Broad Institute of MIT and Harvard; he is also Professor in the Dept of Brain and Cognitive Science at MIT. Previously (2008-2019), Sheng was Vice-President for Neuroscience at Genentech, a leading biotech company, where he was head of neuroscience research and early development. Prior to joining Genentech, Dr. Sheng was the Menicon Professor of Neuroscience at MIT, as well as Investigator of the Howard Hughes Medical Institute.  Sheng received a BA from Oxford University (UK) and obtained his medical degree and training in internal medicine at London University (UK).  He also holds a PhD in molecular genetics from Harvard University. Following his postdoctoral work in neuroscience at the University of California, San Francisco, Dr. Sheng served on the faculty at Massachusetts General Hospital and Harvard Medical School before joining MIT.  Elected as Fellow of the Royal Society (UK), Fellow of the Academy of Medical Sciences (UK), Fellow of the American Association for the Advancement of Science, and recipient of the 2020 Julius Axelrod Prize from the Society for Neuroscience, Dr. Sheng is author of more than 200 peer-reviewed publications focused on the molecular cellular biology of brain synapses and the mechanisms of nervous system diseases.</p>	Yes/No	https://www.broadinstitute.org/bios/morgan-sheng
Startup	Robert Schultz		Founder, Massnex	Robert_Schultz.jpeg	<p>Robert Schultz is a life science entrepreneur, professor, and patient advocate from Boston. As the Founder and Managing Director of Massnex, he utilizes science diplomacy to engage biotech ecosystems and align the incentives of academia, industry, government, and philanthropy to advance patient advocacy. He works with the world's leading biopharmaceutical ecosystems to help companies understand the best practices for success in the Boston ecosystem.</p>	Yes/No	https://www.linkedin.com/in/roberteschultz/
workshop1	Jason Lin		Senior Application Scientist and Market Development at LUMICKS	Jason_Lin.jpeg	<p>Jason’s long-standing interest is to connect newly developed biotechnologies to the real world and facilitate the adoption process to improve human health. Jason received his Ph.D. in Biophysics at Johns Hopkins University, where he built advanced microscopes and engineered light-sensitive enzymes as tools to study protein−nucleic acid interactions. During his Ph.D. training, Jason did an internship where he helped philanthropists facilitate the studies and the development of translational medicine in rare diseases by engaging private funding opportunities with researchers and physicians. Inspired by how scientific discoveries can be accelerated through business means, he joined LUMICKS in 2020. Jason currently works as a Senior Application Scientist and Market Development. He focuses on identifying new market segments and is involved in developing and implementing new product features to serve the unmet needs. Jason has enjoyed sharing his career experiences since 2012. He has been invited as a panelist to discuss career development in several organizations. He is currently serving as a member of the Professor Rounds Program organized by the American Society for Biochemistry and Molecular Biology.</p>	Yes/No	https://www.linkedin.com/in/jasonctl
workshop1	Michael Dubrovsky		Co-founder, SiPhox	Michael_Dubrovsky.png	<p>Michael Dubrovsky is a serial entrepreneur, scientist, and a co-founder of SiPhox. SiPhox is a Khosla Ventures and Y Combinator-backed Boston startup that is miniaturizing proteomics using silicon photonic chips. Michael is also a co-founder at PoWx, an optical computing research non-profit focused on decreasing Bitcoin’s energy consumption. Before SiPhox, he was a researcher at MIT and Technion, studying dewetting processes in thin-film materials. Previously, Michael co-founded a commercial electric vehicle charging startup, Simply Grid, which was acquired by MOVE Systems, where Michael spent several years establishing a supply chain in Asia and a factory in Grand Rapids, Michigan.</P>	Yes/No	https://www.linkedin.com/in/michael-dubrovsky/
workshop1	Lo-I Cheng		Senior research associate, Beam Therapeutics	Lo-I_square.jpeg	<p>Lo-I received her MSc in Pharmaceutical Sciences at Northeastern University. During her studies, with the help from the program, she took the opportunity to gain her research experience in the industry as a Co-Op at Alexion and Biogen, consecutively. There she acquired a variety of cellular/molecular biology skillsets that led her to Beam therapeutics after graduating. At Beam, Lo-I applies her previous experiences to provide life-long cures to patients suffering from serious diseases using cutting-edge base editing technologies, with a focus on liver diseases.</p>	Yes/No	https://www.linkedin.com/in/lo-i-cheng-551256117/
workshop1	Christina Haddad		Intern, Agios pharmaceuticals	Christina-pic_square.jpeg	<p>Christina is a fourth-year Ph.D. candidate in Biochemistry and Structural Biology at Case Western Reserve University. Her focus is the study of viral RNA and proteins in terms of their structural properties and interactions in viruses like coronaviruses and enteroviruses. In hope to apply her research skills in industry, Christina is perusing a summer internship with agios pharmaceuticals this year to help pave the way for an industrial position. </p>	Yes/No	https://www.linkedin.com/in/christina-haddad-phd-928690a7/
Academic	Meng-Ju Wu		Research fellow, Massachusetts General Hospital	Meng-Ju_Wu.jpg	<p>Dr. ​​Meng-Ju Wu obtained his bachelor’s and master’s degrees from National Yang-Ming University. He conducted his doctoral research in Dr. Alice Chang’s laboratory at Purdue University. Meng-Ju is now a postdoctoral fellow of the American Cancer Society (ACS) with Dr. Nabeel Bardeesy and Dr. Robert Manguso's co-mentorship at Massachusetts General Hospital (MGH). His research focuses on how tumor metabolism affects tumorigenesis and the tumor microenvironment.</p>	Yes/No	https://scholar.harvard.edu/mjwu/research-interest
Startup	Samuel Chen		President and CEO, AIxMed	Samuel Chen_square.jpeg	<p>With 30 years’ experience in software development, Mr. Samuel Chen is the president and CEO for AIxMed, a venture backed startup company founded June 2018 focusing on applying machine learning in medicine.  The company develops AI assisted computational cytopathology solutions, and is currently collaborating with hospitals, university, research institute, and medical device companies. </p>	Yes/No	https://www.aixmed.com/
Startup	Will McLean		Co-founder, Frequency Therapeutics	Will_McLean_square.jpeg	<p>Will McLean is a co-founder of Frequency Therapeutics, a company primarily seeking to develop a drug treatment to reverse hearing loss. As an undergraduate, McLean studied biology at Tufts University before going on to attain a Ph.D. at the Massachusetts Institute of Technology within the Harvard-MIT Division of Health Sciences and Technology. While at MIT, his doctoral research elucidated the distinct progenitor cell types that exist within the inner ear and their capacity to form sensory cells and neural cell types. As a postdoctoral fellow at Harvard Medical School, Will investigated the use of small-molecule drugs to manipulate molecular signaling pathways to promote regeneration of inner ear sensory cells. Frequency Therapeutics is now using insights from Will's work to develop drugs to drive regeneration throughout the body, with a lead program in treating hearing loss by regenerating lost sensory cells. Will's work has led to over 30 patent filings and 12 granted patents to date. He has been recognized as an IDEA2 awardee by Harvard-MIT, a leader in Regenerative Medicine and Cell Therapy by Sartorius and Science, a 40 Under Forty Business Leader by the Hartford Business Journal, and one of the top 35 Innovators Under 35 by MIT Technology Review.</p>	Yes/No	https://www.frequencytx.com/	
Trending	Yi-Hsiang Hsu		Co-Director Geriomics Program, Marcus Institute for Aging Research, Harvard Medical School	yi-hsiang-hsu.jpeg	<p>Dr. Hsu has led multiple large-scale whole genome sequencing (WGS), genome-wide association study (GWAS) and Multi-OMICS projects on metabolic-relevant disorders, cardiovascular disorders, musculoskeletal disorders and neuropsychiatric disorders. He has published 120 papers about human genetics and statistical genetics and is regarded as one of the leading experts in the field of using sophisticated statistical genetics and AI deep-learning machine-learning to conduct advanced statistical analysis.</p>	Yes/No	https://www.linkedin.com/in/yi-hsiang-hsu-379b2839/
Trending	Bin li		Director of Computational Biology	Bin_li.jpeg	<p>Dr Li leads a computational biology team with over a dozen PhD scientists, provding translational bioinformatics supports across oncology, GI, NS and rare disease therapeutic areas.Support Takeda’s clinical programs: accountable for omics clinical biomarker data QC, process, and clinical database deposit; collaborate with translational science, biostatistics, clin pharm and other teams on supporting clinical programs’ exploratory analysis and translational research efforts; utilizing AI/ML approaches for drug sensitivity predictions.</p>	Yes/No	https://www.linkedin.com/in/bin-li-b6410b4/
workshop1	Wan-Chih Su		Bioprocess Analytical Scientist, Sanofi-Genzyme	Wan-Chih_Su.png	<p>Wan-Chih received her PhD in Chemistry from UC Davis, where she focused on determining how macromolecular crowding and liquid-liquid phase separation affects cellular response to osmotic stress from a chemical and physical points of view. She also worked on developing potent membrane-disrupting antiviral peptides with the application of all-synthetic model membrane system, combinatorial peptide synthesis and screening of synthetic peptides. During her PhD, Wan-Chih did an internship at 23andMe to develop analytical assays supporting antibody drug discovery. Inspired by knowing how fundamental science could link and contribute to the real world, she joined Sanofi-Genzyme in 2021. She now focuses on developing various analytical assays to support process and manufacturing development of genomic medicine.</p>	Yes/No	https://www.linkedin.com/in/wan-chih-su-a03200169/
workshop2	I-hung Shih		Head of Biotech Private Investment,Wellington	I-hung_Shih.jpeg	<p>I-hung Shih is Head of Biotech Private Investment at Wellington. She deploys a fundamental approach to evaluate investment targets leveraging her integrative experience from basic science, drug discovery, product development, market assessment and financing strategy. Previously, I-hung covered US large cap Biotech at T Rowe Price in Baltimore, and Biopharma sector at Temasek based in NYC. In her three years at Credit Suisse Biotech Investment Banking , she advised biotech companies on financing strategy and managed more than $20 billion in strategic and financial transactions. Notable transactions include sale of Inhibitex to BMS, acquisition of Idenix by Merck, and IPOs/Follow-Ons of Receptos and Enanta.Prior to that, I-hung served various capacities at Gilead Sciences, from drug discovery, business development and commercial strategy. She was Biology Lead for both HCV nuc and NS5A programs, and later became Commercial Strategist for Hepatology franchise (HCV, HBV and NASH), assessing market opportunity and competitive landscape for both internal and external pipeline.</p>	Yes/No	https://www.linkedin.com/in/i-hung-shih-81b6094/
workshop2	Wei-Chien Hung		Senior Engineer/Manger, Takeda	Wei-Chien_Hung.jpeg	<p>Wei Chien (Wayne) Hung works at Takeda pharmaceuticals as a Sr Engineer II/manager from upstream bioprocess in Manufacturing Sciences and Technologies. In Takeda, Wei Chien focuses on driving technology initiatives to incorporate Industry 4.0 into bioprocess and developed strategies to raise productivity for commercial pipelines. Previously Wei Chien worked in Biogen and Alexion (now AstraZeneca) as bioprocess scientist. Wei-Chien also currently works as part time corporate faculty in Harrisburg University lecturing bioprocess. Prior to entering to pharmaceutical industry Wei Chien graduated with Chemical and Biomolecular Engineering  PhD degree from Johns Hopkins University and was also working as a postdoctoral researcher at Yale Medical school. While not working, Wei Chien enjoys Ikebana, Bonsai collection, and ancient armor modeling.</p>	Yes/No	https://www.linkedin.com/in/wei-chien-hung-91a27385/details/experience/
workshop2	Hsiao-Ling Hung		Senior Vice President, Ambrx	Hsiao-Ling_Hung.jpeg	<p>Hsiao-Ling is currently Head of Regulatory Affairs and Quality Assurance at Ambrx, a public clinical-stage biotech company that focuses on developing Engineered Precision Biologics (Ambrx.com, NYSE:AMAM). Hsiao-Ling was previously Senior Director in Global Regulatory Sciences at Bristol-Myers Squibb, leading regulatory strategy and managing regulatory staff for the Opdivo (anti-PD1) and Yervoy (anti-CTLA4) lung cancer and gastric cancer portfolios. Prior to BMS, Hsiao-Ling spent 10 years at Janssen Pharmaceutical Companies of Johnson & Johnson, first as an Asia Pacific Latin America Regulatory Lead, then a North America Regulatory Lead in Oncology. She led the regulatory strategy and execution for the erdafitinib (FGFR inhibitor) program from first in human study to NDA approval. Prior to a career in regulatory affairs, Hsiao-Ling was a scientist for over 20 years. At Genaera Corporation, a biopharmaceutical company, she led the discovery and preclinical research programs of compounds across multiple therapeutic areas, including oncology, ophthalmology, metabolic disease and respiratory disease. Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania.</p>	Yes/No	https://www.linkedin.com/in/hsiao-ling-hung-phd-rac-7771113/details/experience/
workshop2	Jenny Shu		Director and Immunology Biology Team Lead, Synlogic	Jenny_Shu.jpeg	<p>Jenny is an immunologist at heart with academic track-record at leading tumor immunology and immune tolerance labs. She has further grown as a drug hunter in the biotech sector for the past 9 years to ultimately impact patients. Currently, Jenny is the Director and Immunology Biology Team Lead in Synlogic Therapeutics, leading discovery biology to advance Synthetic Biotic medicines in GI and inflammation, with focus on Inflammatory Bowel Disease (IBD). Prior to joining Synlogic, Jenny was a Principal Scientist / Associate Director in Cygnal Therapeutics as its first employee, and played a large role in building the company's scientific strategy and strategic portfolio pipeline. Jenny received her Ph.D. in Microbiology, Immunology, & Molecular Genetics at UCLA, and Masters degree in Management, Finance Track at Harvard University, and Bachelor of Science in Microbiology at Georgia Institute of Technology.</p>	Yes/No	https://www.linkedin.com/in/jenny-shu-9859a09/
Lunch	Miao-Chih Tsai		Senior Editor, Cell Press	Miao-Chih_Tsai.jpeg	<p>Dr. Tsai spent her undergraduate years studying biology and exploring the mountains of her native Taiwan before reading for her Ph.D. at the University of Cambridge, UK. She then moved from rainy Britain to sunny California to further study non-coding RNAs at Stanford University. She is interested in all aspects of biology and especially technological innovations that allow for new understanding of fundamental biology and its potential application. Having experienced its power to inspire, she is an ardent proponent of science and strives to help authors convey their discoveries to the largest possible audience for maximal impact within the scientific community and society at large.</p>	Yes/No	https://www.linkedin.com/in/miao-chih-tsai-0a715723/
Lunch	Shian-Huey Chiang		Director, Pfizer	Shian-Huey_Chiang.jpeg	<p>Dr. Shian-Huey Chiang, is currently Director and Head of Emerging Science Biology, Target Sciences, in Emerging Science & Innovation (ES&I) organization in Pfizer, Boston. Her research focuses on target validation in inflammatory diseases, rare diseases, cancers, metabolic syndrome and fibrosis. Shian-Huey received her bachelor’s degree from the Department of Agriculture Chemistry, National Taiwan University in 1991 and a master’s degree in Biochemistry from National Yang-Ming University in 1994. Shian-Huey received her PhD in the Cellular and Molecular Biology Program at the University of Michigan, Ann Arbor in 2001, where she studied the insulin signaling pathway. During her tenure at the University of Michigan, she published numerous first-author papers in Nature, Cell and Nature Medicine. After that, she joined GlaxoSmithKline as an investigator in North Carolina (2011-2015), and joined Pfizer as a Principal Scientist and Senior Principal Scientist at Centers for Therapeutic Innovation (CTI) in Boston (2015~2019).</p>	Yes/No	https://www.linkedin.com/in/shianhueychiang/
Lunch	Jun-Han Su		Research Associate, Wellington Management	Jun-Han_Su.jpeg	<p>I am a physician-scientist passionate about life sciences investing and developing innovative biomedical technologies. I completed my PhD in the lab of Xiaowei Zhuang, the David B. Arnold Jr. Professor of Science at Harvard University and Investigator at the Howard Hughes Medical Institute, where I developed genome-scale imaging tools to study the 3D organization and activity of chromatin in single cells. During my PhD, I also worked with venture capital firms, pharma external innovation, and university tech transfer offices to commercialize early stage life sciences technologies. Prior to that, I obtained a MD and BSc in Physics from National Taiwan University and a MPhil in Bioscience Enterprise from the University of Cambridge as a Chevening Scholar.</p>	Yes/No	https://www.linkedin.com/in/jun-han-su-md-phd-46731237/
breakfast	Yung-Chi Huang		Postdoctoral Researcher, MIT	Yung-Chi_Huang.jpeg	<p>Dr. Huang obtained her Ph.D degree at U Mass Chan Medicial School where she studied how mutated voltage-gated calcium channels lead to excitatory-inhibitory imbalance. She is currently a postdoctoral researcher in the Picower institute at MIT. Her research focuses on how neurons utilize different mechanisms to simultaneously modulate multiple circuits and therefore promote behavioral coordination. </p>	Yes/No	
breakfast	Yu-Hung Hung		Postdoctoral Researcher, Donald Danforth Plant Science Center	Yu-Hung_Hung.jpeg	<p>Dr. Yu-Hung Hung obtained her bachelor degree from National Chung Cheng University. She is currently a postdoctoral researcher in Dr. Keith Slotkin's lab at Donald Danforth Plant Science Center at St. Louis. Her research projects in Slotkin lab focus on studying the regulation of RNAi gene silencing. Before that, Yu-Hung earned her Ph.D. in Plant Biology  at Dr. Tzung-Fu Hsieh's Lab in North Carolina State University studying  DME-mediated active DNA demethylation, which is critical for embryo and endosperm development. Yu-Hung is also the 2021-2022 Co-President of Midwest Taiwanese Biotechnology Association.</p>	Yes/No	https://www.linkedin.com/in/yuhunghung/
breakfast	Jeng-Shin Lee		Chief Scientific Officer, AB Biosciences	Jeng-Shin_Lee.jpeg	<p>Seasoned biotech executive, molecular biologist by training, with medical background and a wide range of academic and industry experience. Track record includes the development of protein biologics, gene and cell therapy, from exploratory to preclinical phase, process development to cGMP manufacturing in support of investigational new drug (IND) application, as well as successful product out-licensing. Well versed in all commonly used expression and viral gene transfer systems, molecular and functional characterization of immunological proteins across species. Extensive experience in developing and securing intellectual property assets, managing international collaboration, as well as negotiation for various contracts and partnership agreements.  Leadership and management experience in both large and small organizational settings.</p>	Yes/No	https://www.linkedin.com/in/jeng-shin-lee-7624985/
breakfast	Yung-Chih Cheng		Principal Scientist, Pfizer	Yung-Chih_Cheng.jpeg	<p>Yung-Chih obtained his Ph.D. from National Taiwan University and completed postdoctoral training in Clifford Woolf lab at Boston Children’s Hospital/Harvard Medical School to study diverse biological characteristics in neurons after injury. His expertise is primarily in neuron-immune interaction and leveraging stem cell/gene-editing technologies modeling neurological disease models. He is now a principal scientist at Pfizer, leading target validation in rare diseases, particularly in repeat expansion disorders, to advance the rare disease drug portfolio at Pfizer. </p>	Yes/No	
breakfast	Fu-Kai Hsieh		Senior Scientist, Arbor Biotechnologies	Fu-Kai_Hsieh.jpeg	<p>Chih-Chun Lin (also goes by Charles) received his medical degree from the National Taiwan University. He subsequently pursued a PhD in Neuroscience at Johns Hopkins, focused on single-cell electrophysiology and neuronal function. Charles then finished 	Yes/No	https://www.linkedin.com/in/fu-kai-hsieh-491a82b9
breakfast	Tzu-Hsing (April) Kuo		Associate Principal Scientist, Merck	Tzu-Hsing_Kuo.jpeg	<p>April specializes in early stage drug discovery in Biologics with expertise on cell-based characterization of drug candidates. She joined Merck recently as a result of an acquisition of her former company, Acceleron Pharma, which focused its research and drug development efforts in the human TGF-beta superfamily, and hematologic and pulmonary diseases. Prior to Acceleron, April was trained as a molecular and cell biologist throughout her academic careers from Rutgers University (PhD), University of Pennsylvania, and Brigham and Women’s Hospital (Postdocs).</p>	Yes/No	https://www.linkedin.com/in/tzu-hsing-april-kuo-b4890549/
breakfast	Hsiao-Ying (Monica) Wey		Assistant Professor, Massachusetts General Hospital, Harvard Medical School	Hsiao-Ying_Wey.jpeg	<p>Dr Wey obtained her PhD degree in Medical Physics at the University of Texas Health Science Center at San Antonio.She is currently the Director of Translational Imaging of Chemical Neuroscience Program to develop and apply state-of-the-art neuroimaging techniques to study brain function.</p>	Yes/No	https://weylab.martinos.org
breakfast	Jerry (Chih-Chung) Lin		Postdoctoral Researcher, Massachusetts General Hospital, Harvard Medical School	Jerry.jpeg	<p>Chih-Chung “Jerry” Lin is a postdoctoral researcher in Dr. Rudolph Tanzi’s group at the Genetics and Aging Research Unit within the Department of Neurology. He conducted his doctoral research in Dr. Brian Edelson's laboratory at Washington University in St. Louis. His current research focuses on how immune cells affect Alzheimer's pathology. Dr. Lin was a former BTBA co-chair from 2019 to 2020. He co-founded Open Box Science (@OpenBoxSci) in 2020.</p>	Yes/No	https://www.linkedin.com/in/chih-chung-lin-680b48113/
breakfast	An-Chi Cheng		Ph.D. candidate, University of Florida	An-Chi_Cheng.jpeg	<p>An-Chi Cheng obtained her master degree from Department of Life Science at National Taiwan University. She is a Ph.D. candidate in Department of Large Animal Clinical Sciences and Cervidae Health Research Initiative at University of Florida. Her research forcuses on veterinary epidemiology, emerging infectious diseases, and antimicrobial resistant in Cervidae. An-Chi is the 2021-2022 Co-President of Midwest Taiwanese Biotechnology Association and treasurer of UF Veterinary Graduate Student Association.</p>	Yes/No	https://www.linkedin.com/in/an-chi-cheng-114b81122/
breakfast	Dian-Jang Lee		Scientist, Takeda	Dian-Jang_Lee.jpeg	<p>Dr. Dian-Jang Lee obtained his PhD from Ludwig Maximilian University of Munich (Germany). His research focuses on cancer immunotherapy using non-viral drug delivery systems. He is currently working on development of oncology cell therapies at Takeda (Cambridge, MA).</p>	Yes/No	https://www.linkedin.com/in/dian-jang-lee-415624102/
breakfast	Ho-Chou Tu		Associate Director, Alnylam Pharmaceuticals	Ho-Chou_Tu.jpeg	<p>Ho-Chou holds a PhD in Molecular and Cell Biology from Washington University in St. Louis, where she studied the various cell death mechanisms in normal and cancer cells. Her post-doctoral training was done at Boston Children’s Hospital/Harvard Medical School, where she focused on investigating the roles of stem cell factors in solid tumor development and progression. In 2015, she joined Alnylam Pharmaceuticals, the leading biotech developing a world class platform of RNAi therapeutics. In 2018, Alnylam successfully received the first ever RNAi therapeutics approval by the FDA and currently has 4 commercial and 10+ late and early stage clinical stage programs in the pipeline. Ho-Chou leads a multidisciplinary team in the “Next Wave” Liver group with the mission to fuel and expand the future Alnylam liver pipeline. She also serves as research program lead in several pre-clinical and clinical stage programs, focusing on NASH, cardiometabolic and rare genetic diseases. </p>	Yes/No	https://www.linkedin.com/in/ho-chou-tu/
breakfast	Chi-Hsiu (Zoe) Liu		Serior Scientist, Editas Medicine	zoe.jpeg	<p>Dr. Liu obtained her Ph.D. in Anatomy and Cell Biology from National Taiwan University and had her postdoctoral training in the Department of Ophthalmology at Boston Children’s Hospital/HMS. Her projects focused on key regulators that affect retinal degenerative diseases by integrating molecular and cell biology, anatomy, developmental biology, and vascular biology. She is currently a senior scientist at Editas Medicine working on in vivo pharmacology and toxicology for proof-of-concept in gene therapy for inherited retinal diseases.</p>	Yes/No	https://www.linkedin.com/in/chi-hsiu-zoe-liu-8436417a/
breakfast	Jay (Chih-Chieh) Wang		Principal Scientist, LogicBio Therapeutics	Jay.jpeg	<p>Jay received his Ph.D. in Neuroscience from Tulane Univerisy, and he completed his postdoc training at Harvard Medical School. He joined industry as a scientist to develop antibodies at BioLegend. He then transited to a startup Cygnal Therapeutics to do early discovery research. At Cygnal he led several projects to study neuronal roles in diesease progression by combing genetic, pharmacological, as well as electrophysiological approaches. Currently he is leading a group at LogicBio to develop plateforms and to treat rare disease using AAV. He is also actively volunteering in several non-profit organizations including Monte Jade New England and Boston Taiwanese Biotechnology Association.</p>	Yes/No	https://www.linkedin.com/in/jay-032045a0/
breakfast	Margaret (Chia-Ying) Wey		Director, Clinical Development Scientist, AstraZeneca	Margaret_Wey.jpeg	<p>Dr. Wey focused on neuropharmacology in neurodegenerative diseases and the genetic underpinning of psychiatric disorders. Both projects were awarded grant funding supporting research and development of in-vitro/in-vivo models to identify druggable targets. She also worked with multiple teams testing anti-aging interventions funded by the NIH project grant. Dr. Wey has transitioned from bench to bedside and shifted my focus to oncology clinical trials. She has been managing over 100 clinical trials in various disease groups: Multiple Myeloma, Gastrointestinal Malignancies, Genitourinary Oncology, Leukemia, Bone marrow transplant, and Cell therapy – applying her knowledge in clinical healthcare, research, and regulations. She has now joined the sponsor industry side. She has been working on lymphoma programs, developed clinical protocols and related documents, cleaned up and analyzed data, and submitted an NDA, which received accelerated approval by the FDA.</p>	Yes/No	https://www.linkedin.com/in/margaretwey/
breakfast	Bobbi Hsieh		Clinical Trial Manager, Fate Therapeutics Inc 	Bobbi_Hsieh.jpeg	<p>Bobbi is an Clinical Trial Manager at Fate Therapeutics since Aug 2020. Her specialty is clinical trial management in the cell therapy field. Bobbi received her MS degree in Drug Development from UC San Diego in 2020 and gained very comprehensive insights of the drug development industry. Bobbi joined SoCal TBA since 2020 and now is 2022 Co-President. With her scientific background and strong industry connections, she hopes to connect people and build up a network of the Biotech/ Pharma industries between Taiwan and the U.S.</p>	Yes/No	https://www.linkedin.com/in/bobbi-hsieh/
breakfast	Ling-Fang Tseng		Principal Clinical Scientist, Vertex Pharmaceuticals	Ling-Fang_Tseng.jpeg	<p>Dr. Ling-Fang is a self-motivated and organized professional offering a strong multidisciplinary background with extensive experiences in polymer science and translational science, complemented by excellent interpersonal skills and adaptability for new projects and environments. She has experience in global Phase II clinical trials and IND-enabled GLP toxicology studies. She completed her Ph.D. degree in Bioengineering at Syracuse University.</p>	Yes/No	https://www.linkedin.com/in/lingfangtseng/
breakfast	Yvonne Meng		Principal Scientist, Johnson & Johnson	Yvonne.jpeg	<p>Yvonne Meng is currently a Principal Scientist, Biologics Discovery, Therapeutic Discovery at Johnson & Johnson. Her expertise and research interests focus on preclinical therapeutic biologics discovery and protein engineering including monoclonal antibody, multispecific antibody, VHH, fusion proteins for drug discovery and development, basic biology of drug target validations, understanding molecular pathways, and translational research of human diseases in Immuno-Oncology, Neuroscience, Cardio-Renal, Eye & Metabolic Disorders, and Infectious Disease. Prior to Johnson & Johnson, she used to be a Senior Manager at Entrada Therapeutics (2020), Senior Scientist at Merck & Co. (2016-2020), Staff Scientist at Takeda (2015-2016), and a Postdoctoral Research Fellow at Pfizer (2014-2015). Yvonne was born and grew up in Taiwan. She received her PhD in Biomedical and Biological Sciences under the supervision of Dr. Moonsoo Jin from Cornell University in 2013, studying aptamer discovery on yeast display platform for diagnostics and imaging purposes. She received her BSc in Life Sciences from National University of Kaohsiung in 2006, and worked as a research associate from the Institute of Biological Chemistry, Academia Sinica in Taipei, Taiwan during 2006-2008. Outside of work, she actively participates in activities strengthening networking among academic and industrial bioscience; she also serves as a Board Member of Boston Taiwanese Biotechnology Association (BTBA). In her spare time, she enjoys food with friends, traveling, and iPhone photography.</p>	Yes/No	https://www.linkedin.com/in/hwyvonnemeng/
breakfast	Hao-Chen (Vivian) Chang		Research Scientist, Omega Optics Inc.	Vivian.jpeg	<p>Dr. Hao-Chen Chang has been in the biomedical engineering field for more than five years, including cell biology, bioinformatics, tissue regeneration engineering, and microfluidics. She is well-experienced in novel biomedical microfluidic product development and launches to the market. She currently focuses on the product development of biosensors, especially in vitro diagnostic (IVD) devices. Hao-Chen Vivian is also the 2022 Co-Chair of Texas Taiwanese Biotechnology Association.</p>	Yes/No	www.linkedin.com/in/vivianhc-v2244181 
breakfast	Hung-Ying Lin		Senior scientist, BMS	Hung-Ying_Lin.jpeg	<p>Dr. Hung-Ying Lin is a Senior Scientist at Bristol Myers Squibb (BMS), Translational Bioinformatics. In this role, he is providing statistical & computational tools for various genomics datasets in several clinical trials and research projects. Before joining BMS, Dr. Lin was a Bioinformatic scientist at a molecular diagnosis company, Sema4, he was a major developer for an NYDOH approved oncology whole-exome sequencing pipeline running on AWS. His specialty covers cloud computing, oncology, computational biology, and genetics.</p>	Yes/No	https://www.linkedin.com/in/hung-ying-lin-37001578/
breakfast	Chen-Ching (Vicky) Yuan		Scientist, EMD Serono	Chen-Ching_Yuan.jpeg	<p>Dr. Yuan obtained her bachelor degree from Tunghai University and Ph.D. degree in Molecular and Cellular Pharmacology at the  University of Miami. She has finished her postdoc training as Sackler Scholar at the University of Washington and Massachusetts General Hospital, Howard Hughes Medical Institute. Her research was focused on studying cardiovascular and muscle disease mechanisms with X-ray diffraction in rodent models and mitochondria physiology.   Currently, She works in EMD Serono as a Scientist to develop the therapeutic antibodies for oncology and immunology research and disease.</p>	Yes/No	https://www.linkedin.com/in/chen-ching-yuan/
breakfast	Kenneth Chih-Wei Chen		Business Development Manager (Drug Licensing), ACROBiosystems Inc.	Kenneth.jpeg	<p>Dr. Chen (Ken) obtained his Master of Science from National Taiwan University, PhD and PostDoc in Dr. Joerg Distler’s lab at University Hospital Erlangen-Nürnberg, Germany, and MBA from Hult International Business School (Boston and San Francisco). Ken just finish his role as an in-house management and scientific consultant for ZAGENO, a life Science R&D e-commerce in Europe and North America and move to ACROBiosystems / bioSeedin as a BD manager for drug licensing in and out! Experience across immunology / rare disease, entrepreneurship, business development, and business management consultant.</p>	Yes/No	https://www.linkedin.com/in/kenneth-chih-wei-chen/
breakfast	Annabelle Ooi		Associate Director, Market Access Excellence Operations, Sanofi	Annabelle_Ooi.jpeg	<p>Annabelle is an Associate Director in Market Access Excellence Operations at Sanofi. In her role, she collaborates cross functionally with account directors within the Sanofi General Medicines portfolio to lead strategic and operational initiatives in line with the overall market access business objectives, particularly those centered on formulary access and market uptake. Prior to this role, Annabelle has spent five years in immunology research across academic, biotechnology startup and pharmaceutical settings. Annabelle holds an MBA with a focus in Business Analytics from University of Massachusetts Amherst and a BA in biology from Mount Holyoke College.</p>	Yes/No	https://www.linkedin.com/in/annabelleooi/
breakfast	Amy Shyu		Associate, Mckinsey	Amy_Shyu.jpeg		Yes/No	https://www.linkedin.com/in/amy-shyu-bpharm-ms-phd-5959b05b/
breakfast	Sabrina Yang		Principal, Flagship Pioneering	SabrinaYang.jpeg	<p>Sabrina Yang is a principal at Flagship Pioneering. In this role, she works as part of a team of entrepreneurial scientists to conceive, create, resource and develop the next generation of Flagship’s first-in-category and fund early-stage companies. Prior to joining Flagship, Sabrina was a postdoctoral researcher and an NSF-funded translational fellow at MIT, where she worked with MIT’s venture mentoring service team to bring her academic research from the bench to commercialization. Sabrina holds a Ph.D. and M.S. in materials science and engineering from MIT and a B.S. in materials science and engineering from National Tsing Hua University in Taiwan, where she graduated summa cum laude and was valedictorian.<p>	Yes/No	https://www.linkedin.com/in/sabrina-yang-a0438b53/
breakfast	Pin-Hsian Huang		Marketing Manager, Bon Opus Biosciences	Pin-Hsian_Huang.jpeg	<p>Pin-Hsian Huang (Sean) has worked in the preclinical CRO field for over two years with experience in marketing and product management. He has also been volunteering as Co-organizer in Bay Area Taiwanese Biotech Association (BATBA) since 2020. Sean received his master's degree in Translation Medicine at UC Berkeley and UCSF. Before coming to the US, Sean has a few internship experiences in startups and completed his bachelor’s degree in Biochemistry at NTU.</p>	Yes/No	https://www.linkedin.com/in/pinhsianhuang/
breakfast	Winnie Tung		Senior Scientist, Sanofi	Winnie_Tung.jpeg	<p>Winnie obtained her Ph.D degree in Immunology from Baylor College of Medicine, where she studied the roles of Let-7 miRNAs in COPD and identified a novel signaling pathway induced by proteolysis of Fibrinogen for initiation of allergic asthma and innate antifungal defense in David Corry’s lab. She joined Sanofi in Dec. 2018 and is currently a senior scientist in Immunology & Inflammation Research Therapeutic Area, focusing on early drug discovery for type 2 inflammatory diseases such as asthma and AD. She has led several programs with external partners globally and worked on various drug modalities, including monoclonal and multispecific antibodies, nanobodies, PROTACs and small molecule inhibitors/ agonists.</p>	Yes/No	https://www.linkedin.com/in/hui-ying-winnie-tung-4778a074/
breakfast	Ching-Lin Hsieh		Principal Scientist, Sanofi	Ching-Lin_Hsieh.png	<p>Ching-Lin obtained his PhD from Cornell where he studied bacterial pathogenisis and pathogen-host interactions. Then he joined Jason McLellan's team at UT Austin to learn structure-based vaccine design. During his postdoc training, he became familiar with X-ray crystallography and single particle cryoEM. He was able to use high-resolution structures to guide viral antigen designs, accelerating the vaccine developement during the pandemic. He just joined Sanofi and will continue working on vaccine antigen design.</p>	Yes/No	https://www.linkedin.com/in/ching-lin-hsieh-046238215/
breakfast	Wan Hsi (Wendy) Chen		Research Associate, UT Southwestern Medical Center	Wendy_Chen.jpeg	<p>Wan Hsi (Wendy) Chen received her master’s degree at Texas Tech University Health Sciences Center. She worked on Neuroblastoma study in Dr. Reynolds' lab for five years. She is well-experienced in establishing Neroublatoma Patient-Derived Xenograft (PDX) mice models and cell lines. Currently, she joined Dr. Yan's lab at UT Southwestern to research in Immunology/Neurodegeneration field. Wendy is also the 2022 Co-Chair of Texas Taiwanese Biotechnology Association.</p>	Yes/No	https://www.linkedin.com/in/wan-hsi-chen-983876118
breakfast	Chih-Chi (Jimmy) Chu		Associate Director, mRNA Process Development, 2seventy bio	Jimmy_Chu.jpeg	<p>Dr. Chu obtained his Ph.D. in Chemistry from University of Illinois at Urbana-Champaign studying in vitro selection and artificial design of catalytic DNAs. He then went on to pursue his biotech industry career developing manufacturing processes for mRNA and plasmids in gene therapy. He is currently an Associate Director at 2seventy bio leading the mRNA process development team and advancing 2seventy's gene editing programs. </p>	Yes/No	https://www.linkedin.com/in/chih-chi-jimmy-chu-526b0073/`;

const tsv_array = tsv_str
	.split('\n')
	.map(el => el.split('\t'))
	.filter(el => el[1])
	.map(el => {
		return {
			'name': el[1].trim() || null,
			'nameCh': el[2] || null,
			'affiliations': el[3] ? el[3].split(';') : [],
			'imgFileName': el[4] || 'placeholder.jpg',
			'links': el[7] ? el[7].split(';') : [],
			'description': el[5] || ''
		};
	});

const tsv_dict = {};

tsv_array.forEach(el => {
	el.name.trim() in Object.keys(tsv_dict)
		? false
		:  tsv_dict[el.name.trim()] = el;
});

export const speakersObj = tsv_dict;
